ArticleCancer immunology research2025

ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade.

Hampus Andersson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.